Status:
COMPLETED
Management of OAB in Female Patients .
Lead Sponsor:
Elsayed Abdelhalim Elsayed
Conditions:
Overactive Bladder
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
The objective of this study is to compare the effectiveness of mirabegron, solifenacin, tadalafil (5mg), and their combination in relieving symptoms of overactive bladder (OAB) in a double-blinded pro...
Eligibility Criteria
Inclusion
- Women from 18 to 65 years of age with LUTs due to OAB
Exclusion
- Severe cardiovascular disorders. \\
- Severe neurogenic dysfunction.
- Drug administration which interfere with bladder function .
- Abnormal bleeding profile.
- A verified urinary tract infection as determined by urinalysis and/or urine culture during screening
Key Trial Info
Start Date :
September 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06184334
Start Date
September 14 2022
End Date
December 1 2023
Last Update
April 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kafrelsheikh University hospital
Kafr ash Shaykh, Egypt